Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external video platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name Youtube
Purpose External media

Personalized cancer immunotherapy

No. 09a | 01/03/2017 | by Koh

The new Helmholtz Institute HI-TRON is a collaboration of the German Cancer Research Center (DKFZ) in Heidelberg and the Research Institute for Translational Oncology (TRON) at the University Medical Center of the Johannes Gutenberg University in Mainz. The goal of the partnership is to develop effective immunotherapies and to identify novel biomarkers for assessing the effectiveness of treatment.

© dkfz.de

In recent times, physicians have achieved spectacular clinical successes with cancer immunotherapies. There have even been cases of long-term regression in advanced stage cancers where until now medicine failed to be effective. Cancer researchers aim to adjust these treatments still more precisely to the individual disease. Advanced methods of molecular high-throughput analysis facilitate identifying the targets on cancer cells specifically and thus tailoring immunotherapies to the individual patient.

At the new Helmholtz Institute HI-TRON, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) has now teamed up in this seminal research field with the Research Institute for Translational Oncology (TRON) at the University Medical Center Mainz.

Prof. Dr. Michael Baumann, Chairman of the Management Board of the German Cancer Research Center, said: "For developing novel cancer therapies successfully, it is crucial that researchers, researching physicians and clinicians should all be working hand in hand. In order to make this possible, the German Cancer Research Center relies on collaborations and intensive networking with excellent partner institutions. In TRON we have found an internationally renowned partner with whom we are joining forces to achieve further advances in the principal and seminal area of cancer immunotherapy. We will now be able to join up the strengths of both institutions – in order to offer more effective treatments to cancer patients as swiftly as possible."

Following the start-up phase, HI-TRON will receive annual funding of more than €5 million from the Helmholtz Association. The state of Rhineland-Palatinate and the DKFZ will additionally provide substantial initial financing.

TRON in Mainz is one of the world's leading institutes in research on the identification of biomarkers and personalized immunotherapy. The collaboration with the DKFZ is aimed above all at accelerating the translation of excellent immunology research and innovative therapy approaches into the clinic. Up to now, little is known why immunotherapies are effective in some patients and fail in others. Therefore, another major aim of the new research alliance is to identify biomarkers that facilitate assessing the prospects of success of an immunotherapy before starting treatment.

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Tumour Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS